Log in

Relevant bibliographies by topics / Ribavirine / Books

To see the other types of publications on this topic, follow the link: Ribavirine.

Books on the topic 'Ribavirine'

Author: Grafiati

Published: 4 June 2021

Last updated: 25 May 2024

Create a spot-on reference in APA, MLA, Chicago, Harvard, and other styles

Select a source type:

Consult the top 16 books for your research on the topic 'Ribavirine.'

Next to every source in the list of references, there is an 'Add to bibliography' button. Press on it, and we will generate automatically the bibliographic reference to the chosen work in the citation style you need: APA, MLA, Harvard, Chicago, Vancouver, etc.

You can also download the full text of the academic publication as pdf and read online its abstract whenever available in the metadata.

Browse books on a wide variety of disciplines and organise your bibliography correctly.

1

Thomas, Stapleton, and Royal Society of Medicine (Great Britain), eds. Studies with a broad spectrum antiviral agent. London: Royal Society of Medicine, 1986.

Find full text

APA, Harvard, Vancouver, ISO, and other styles

2

National Institute for Clinical Excellence., ed. Guidance on the use of Ribavirin and Interferon Alpha for hepatitis C. London: NICE, 2000.

Find full text

APA, Harvard, Vancouver, ISO, and other styles

3

Husereau, Donald Robert. Interferon-based therapies for chronic hepatitis C virus infection: An assessment of clinical outcomes. Ottawa: Canadian Coordinating Office for Health Technology Assessment, 2004.

Find full text

APA, Harvard, Vancouver, ISO, and other styles

4

Bruce, Brady, and Canadian Agency for Drugs and Technologies in Health., eds. Pegylated interferon combined with ribavirin for chronic hepatitis c virus infection: An economic evaluation. Ottawa: Canadian Agency for Drugs and Technologies in Health, 2007.

Find full text

APA, Harvard, Vancouver, ISO, and other styles

5

Oluleye, Kunmi. The cure of chronic Hepatitis B: One man's cure, one family's experience. Cambridge, Mass: IROK Solutions, 1996.

Find full text

APA, Harvard, Vancouver, ISO, and other styles

6

Shepherd, J. Combination therapy (interferon alfa and ribavirin) in the treatment of chronic hepattitis C: A rapid and systematic review. Alton: Core Research on behalf of the NCCHTA, 2000.

Find full text

APA, Harvard, Vancouver, ISO, and other styles

7

J, Shepherd, and National Co-ordinating Centre for HTA (Great Britain), eds. Pegylated interferon [alpha]-2a and -2b in combination with ribavirin in the treatment of chronic hepatitis C: A systematic review and economic evaluation. Tunbridge Wells: Gray Publishing on behalf of NCCHTA, 2004.

Find full text

APA, Harvard, Vancouver, ISO, and other styles

8

Karl, Nicholson, ICN Pharmaceuticals inc, and Royal Society of Medicine (Great Britain), eds. HIV and other highly pathogenic viruses. London: Royal Society of Medicine Services, 1989.

Find full text

APA, Harvard, Vancouver, ISO, and other styles

9

United States. Congress. House. Committee on Energy and Commerce. Subcommittee on Oversight and Investigations. FDA regulation of ribavirin: Hearing before the Subcommittee on Oversight and Investigations of the Committee on Energy and Commerce, House of Representatives, One Hundredth Congress, first session, May 28, 1987. Washington: U.S. G.P.O., 1988.

Find full text

APA, Harvard, Vancouver, ISO, and other styles

10

Buskirk, Joris. Ribavirin: Biochemistry, Clinical Applications and Potential Side Effects. Nova Science Publishers, Incorporated, 2013.

Find full text

APA, Harvard, Vancouver, ISO, and other styles

11

Smith, Deb. 48 Weeks...A Journey: Treating for HCV with Pegylated Interferon and Ribavirin. BookSurge Publishing, 2006.

Find full text

APA, Harvard, Vancouver, ISO, and other styles

12

Oluleye, Ibiyinka, Ibibyinka Oluleye, and Kunmi Oluleye. The Cure of Chronic Hepatitis B: One Man's Cure One Family's Experience. Irok Solutions Inc, 1997.

Find full text

APA, Harvard, Vancouver, ISO, and other styles

13

Aerosolized ribavirin in the treatment of respiratory syncytial viral infection in children: A meta-analysis. Ottawa: National Library of Canada, 1995.

Find full text

APA, Harvard, Vancouver, ISO, and other styles

14

Krain, Lisa J., and Kenrad E. Nelson. Hepatitis E Virus. Oxford University Press, 2018. http://dx.doi.org/10.1093/med/9780190604813.003.0006.

Full text

Abstract:

Hepatitis E virus (HEV) poses serious risks to pregnant women and their developing fetuses, including increased risk of pregnancy loss, stillbirth, preterm delivery, and early infant death. Supportive care is currently the standard treatment for pregnant women with HEV infection, but in some cases, ribavirin treatment or early delivery may be indicated. Infants born with acute HEV infection face increased risk of complications and death. Intensive monitoring and support may be required in the neonatal period, particularly for preterm infants. Infants who survive the early neonatal period are likely to recover fully and clear the virus. Immunoassays and molecular methods for diagnosis of HEV have improved markedly over the past decade. New HEV vaccines may provide an opportunity to prevent both maternal illness and mother-to-child transmission (vertical transmission) (MTCT).

APA, Harvard, Vancouver, ISO, and other styles

15

Schechter, Marcos. Viral Hemorrhagic Fevers (Ebola, Lassa, Hantavirus). Oxford University Press, 2016. http://dx.doi.org/10.1093/med/9780199976805.003.0066.

Full text

Abstract:

Viral hemorrhagic fever (VHF) designates diseases caused by enveloped, single-stranded RNA viruses belonging to the families Ebola, Lassa, Hantavirus, and yellow fever. Unifying features include fever, capillary leak, and coagulation defects. These viruses can affect all organ systems; transmission occurs via contact with rodent excretions, either by ingestion or through mucosa or non-intact skin. Aerosolized rodent urine and saliva are also infectious. Person-to-person spread has been documented in Lassa and Machupo viruses, both by direct contact with bodily fluids and by airborne transmission. Thrombocytopenia is a common laboratory finding. Most acutely ill patients have high concentrations of virus in the blood as measured by polymerase chain reaction assay. Clinical differentiation between the various causes of VHF is difficult. Care is supportive. No antiviral drug, including ribavirin, has activity against these viruses. Most of these diseases do not occur naturally in the United States; however, some are considered viable for bioterrorism.

APA, Harvard, Vancouver, ISO, and other styles

16

Mesquita, Emersom C., and Fernando A. Bozza. Diagnosis and management of viral haemorrhagic fevers in the ICU. Oxford University Press, 2016. http://dx.doi.org/10.1093/med/9780199600830.003.0293.

Full text

Abstract:

In a globalized scenario where widespread international travel allows viral agents to migrate from endemic to non-endemic areas, health care providers and critical care specialists must be able to readily recognize a suspected case of viral haemorrhagic fever (VHF). Early suspicion is pivotal for improving patient outcome and to ensure that appropriate biosafety measures be applied. VHFs are acute febrile illnesses marked by coagulation disorders and organ specific syndromes. VHFs represent a great medical challenge because diseases are associated with a high mortality rate and many VHFs have the potential for person-to-person transmission (Filoviruses, Arenavioruses, and Bunyaviroses). Dengue is the most frequent haemorrhagic viral disease and re-emergent infection in the world and, due to its public health relevance, severe dengue will receive special attention in this chapter. The diagnosis of VHFs is made by detecting specific antibodies, viral antigens (ELISA) and viral nucleic acid (RT-PCR) on blood samples. Supportive care is the cornerstone in the treatment of VHFs. Ribavirin should be started as soon as a case of VHF is suspected and discontinued if a diagnosis of Filovirus or Flavivirus infection is established. Adjunctive antimicrobial therapy is usually implemented to treat co-existing or secondary infections. Antimalarial treatment should also be initiated if a malaria test (thick blood films) is not quickly available and/or reliable and patients travel history is compatible. It is always recommended to apply appropriate biosafety measures and notify local infection control unit and state and national authorities.

APA, Harvard, Vancouver, ISO, and other styles

We offer discounts on all premium plans for authors whose works are included in thematic literature selections. Contact us to get a unique promo code!